1. 上海市2023年度“科技创新行动计划”自然科学基金面上项目, 23ZR1448800, 炎症性肠病中GPR65介导JAK-STAT-FOXO通路促进肠上皮屏障功能, 2023/04-2026/03，在研，主持

2. 爱在延长炎症性肠病基金会，2022年青峰科研资助项目，CCCF-QF-2022C27-19，炎症性肠病患者并发冠状动脉微血管功能障碍的调查研究，2023/01-2025/12, 在研，主持

3. 国家自然科学基金青年项目, 81800487, TOB1对炎症性肠病肠黏膜组织内Th1/Th17细胞激活的免疫调节机制研究,2019/01-2021/12, 结题,主持

4. 同济大学青年人才培育类青优项目, 22120180574, TOB1对炎症性肠病肠黏膜组织内Th1/Th17细胞激活的免疫调节机制研究,2019/01-2020/12, 结题,主持

5. 同济大学附属第十人民医院攀登人才计划，优秀青年医师A类，炎症性肠病合并心肌缺血发生风险的相关研究，2018/09-2020/08，结题，主持

6. 同济大学基础研究能力提升计划项目，22120170034，Th22 细胞在炎症性肠病发生发展中的免疫调节机制研究,2017/10-2018/06，结题，主持

7.国家自然科学基金重点项目,81630017,CD177+中性粒细胞在炎症性肠病发生发展过程中的免疫调节机制,2017/01-2021/12，结题,参加

8.国家自然科学基金面上项目,81470822,miR-301a对炎症性肠病Th1和Th17细胞增殖分化的免疫调节作用,2015/01-2018/12, 结题, 参加

一、代表性成果：

(1) Gengfeng Li(#), Ritian Lin(#),  Jian Lin(#),  Xiang Gao, Xiaohan Wu, Qiong He, ZhongshengFeng, Han Gao, Huili Wu, Wei Wu, Leilei Fang(*), Zhanju Liu(*), Intestinalepithelial pH-sensing receptor GPR65 maintains mucosal homeostasis viaregulating antimicrobial defense and restrains gut inflammation in inflammatorybowel disease. Gut Microbes 2023.

(2) Fang, Leilei (#); Gao, Han; Gao,Xiang; Wu, Wei; Miao, Yinglei; Zhang, HJ; Guleng, B; Zhang, H; Wang, YF; Li,MS; Yang, H; Liang, J; Cao, Q; Shen, J; Ran, ZH; Wu, KC; Qian, JM; Chen, MH;Liu, ZJ, Risks of Cardiovascular Events in Patients With Inflammatory BowelDisease in China: A Retrospective Multicenter Cohort Study. Inflamm Bowel Dis2022 06 02;28.

(3) Lin,RT (#); Ma, CY (#);Fang, LL (Fang, Leilei) (#);Xu, CJ ; Zhang, C; Wu, XH; Wu, W; Zhu, RX; Cong, YZ; Liu, ZJ, TOB1 Blocks Intestinal Mucosal InflammationThrough Inducing ID2-Mediated Suppression of Th1/Th17 Cell Immune Responses inIBD. Cell MolGastroenterol Hepatol 2022;13(4).

(4) Yuxia Li, Genmei He, Ruqin Zhong,Xuejuan Li, Huamei Li, Huaqiong Dong, Yun Zhang, Guohong Zhao(*), LeileiFang(*), Intramural colonic signet ring cell carcinoma presenting asintestinal pseudo-obstruction: A case presentation and review of theliterature. Front Oncol 2023;13

(5) Chen Liang(#), Lu Zhanjun(#), Kang Dengfeng,Feng Zhongsheng, Li Gengfeng, Sun, Mingming, Liu Zhanju, Wu Wei(*), FangLeilei(*), Distinct alterations of fecal microbiota refer to the efficacyof adalimumab in Crohn's disease. Front Pharmacol 2022;13

(6) Fang, Leilei(#)(*); Liu,Changqin; Sun, Xiaomin; Liu, Zhanju, Anti-TNF Treatment Failure in a PatientWith Immune Checkpoint Inhibitor-Induced Severe Colitis. Front Oncol 2022;12

(7) Li, Gengfeng(#);Wu, Xiaohan; Gao, Xiang;Lin, Ritian ; Chen, Liang; Sun, Mingming; Jia, Junwan; Liu, Zhanju; Fang,Leilei(*); Wu, Wei(*), Long-term exclusive enteral nutrition remodels thegut microbiota and alleviates TNBS-induced colitis in mice. Food Funct 2022 Feb21;13(4)

(8) LeileiFang(#) , Zhi Pang (#), Weigang Shu, Wei Wu, Mingming Sun, Yingzi Cong,Zhanju Liu(*) , Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 andPromotes Epithelial Repairs in Patients With Crohn's Disease[J].Inflammatorybowel diseases.2018,24(8):1733-44.

(9) Zhou G(#); Yu L(#); Fang L(Fang, Leilei); Yang W; Yu T; MiaoY; Chen M; Wu K; Chen F; Cong Y; Liu Z, CD177(+) neutrophils as functionallyactivated neutrophils negatively regulate IBD[J].Gut.2018,67(6):1052-63.

(10) He,Chong(#), Yu,Tianming(#) , Shi,Yan, Ma,Caiyun, Yang,Wenjing, Fang,Leilei, Sun,Mingming, Wu,Wei, Xiao,Fei,Guo,Feifan, Chen,Minhu, Yang,Hong, Qian, Jiaming, Cong,Yingzi(*),Liu,Zhanju(*), MicroRNA 301A Promotes Intestinal Inflammation andColitis-Associated Cancer Development by InhibitingBTG1.,Gastroenterology,2017.02.10

(11) He,Chong(#) ,Shi, Yan(#) , Wu,Ruijin(#) ,Sun, Mingming, Fang, Leilei, Wu, Wei, Liu, Changqin, Tang, Maochun, Li,Zhong, Wang, Ping, Cong,Yingzi, Liu,Zhanju(*) ,miR-301a promotes intestinal mucosal inflammation through induction of IL-17Aand TNF-alpha in IBD.,Gut,2016.12.01,65(12):1938~1950

(12)Zhou,Guangxi, Yu,Lin, Yang,Wenjing, Wu,Wei, Fang,Leilei, Liu,Zhanju(*) ,Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of InflammatoryBowel Disease.,Mediators Inflamm,2016.01.01,2016:2543070~2543070

(13)Zhou, Guangxi(#),Song,Yang (#),Yang,Wenjing, Guo,Yanmin, Fang,Leilei, Chen,Yamei, Liu,Zhanju (*),ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis ofInflammatory Bowel Disease?,Dig Dis,2016.01.01,34(1-2):90~97

(14)Wu,Wei (#),Song,Yang(#),He,Chong, Liu,Changqin, Wu,Ruijin, Fang,Leilei, Cong,Yingzi,Miao,Yinglei(*), Liu,Zhanju(*),Divalent metal-ion transporter 1 is decreased in intestinal epithelial cellsand contributes to the anemia in inflammatory bowel disease., SciRep,2015.11.17,5:16344~16344

(15)Wu,Wei(#),He,Chong(#),Liu,Changqin, Cao,Anthony T, Xue,Xiaochang, Evans-Marin, Heather L,Sun,Mingming, Fang,Leilei, Yao, Suxia, Pinchuk, Irina V,Powell, Don W,Liu,Zhanju(*), Cong,Yingzi(*),miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responsesin IBD., Gut,2015.11.01,64(11):1755~1764

(16) Fang,Lei-Lei(#),Yu,Hai-Qiong(#), Wu,Rui-Jin, He,Chong, Li,Meng, Yan,Hao,Li,Jian-Jie, Wang,Shuai, Liu,Zhi-Gang, Liu,Zhan-Ju(*),Yang,Ping-Chang(*), Thrombospondin 1 Modulates Monocyte Propertiesto Suppress Intestinal Mucosal Inflammation.,J Innate Immun,2015.01.01,7(6):601~611

(17)Ma,Shibin(#),Shukla,Vipul(#), Fang,Leilei,Gould,Karen A, Joshi,Shantaram S, Lu,Runqing(*),Accelerated development of chronic lymphocytic leukemia in New Zealand Blackmice expressing a low level of interferon regulatory factor 4.,J Biol Chem,2013.9.13,288(37):26430~26440

二、论著之外的代表性研究成果和学术奖励：

 (1) Leilei Fang；Distinct alterations of fecalmicrobiota refer to the efficacy of adalimumab in Crohn's disease，the 10thAnnual Meeting of the Asian Organization for Crohn’s & Colitis (AOCC 2022),Virtual Congrass，2022-6-16至2022-6-18(会议报告)

 (2) Leilei Fang; Zhanju Liu ; Risks of heartevents in Patients with Inflammatory Bowel Disea se in China: A ProspectiveMulticenter Cohort Study, the 8th Annual Meeting of the Asian Organization forCrohn’s & Colitis (AOCC 2020), Busan, Korea, 2020-12-16至2020-12-18(会议报告)

(3) 2020年亚洲炎症性肠病学会（AsianOrganization for Crohn's and Colitis, AOCC）组织年会，investigator award

(4) 方蕾蕾(4/10)；炎症性肠病治疗新靶点筛选和治疗研究及应用，中华医学会，中华医学科技奖，三等奖，2020（刘占举；张小平；吴维；方蕾蕾；孙明明；施嫣红；刘嫦钦；邬瑞金；彭康胜；林日添）

(5) 方蕾蕾(4/10)；炎症性肠病治疗新靶点筛选和靶向免疫治疗研究及应用,中国医疗保健国际交流促进会, 华夏医学科技奖, 二等奖, 2019 (刘占举；张小平；吴维；方蕾蕾；孙明明；施嫣红；刘嫦钦；邬瑞金；彭康胜；林日添)。